← Surfer · Sage hub

Sage — GI: Holobiont Symbiosis & Autoimmune Gastritis

Surfer Coach Sage

1. Framing — compensatory cascade → GI as primary partnership

We are not solo organisms. We are holobionts — chimeric assemblies of eukaryotic host cells and vast microbial communities whose co-evolution solved energy extraction, ordered complexity, immune discrimination, and adaptive resilience in fluctuating environments. The gut biota is the primary ongoing symbiont: the living interface where food becomes metabolic economy, where immune tolerance is educated, where hunger and satiety signals are tuned, and where the inflammatory set-point of the entire body is established and maintained.

Most chronic conditions that dominate modern morbidity — obesity, type 2 diabetes, atherosclerosis, neurodegeneration, autoimmunity, and many aspects of mood and cognitive decline — may be usefully reframed not as discrete organ-specific pathologies with independent causes, but as varied downstream expressions of a single upstream compromise: the fraying of an ancient partnership between eukaryotic host and its bacterial and archaeal partners. Autoimmune gastritis belongs in that same geometry. It is not primarily a story of rogue T cells that decided, for genetic bad luck or molecular mimicry alone, to attack parietal-cell H+/K+-ATPase. It is more usefully read as a downstream expression of chronic mitochondrial energetic shortfall — local in the oxyntic mucosa and systemic — whose consequences include redox stress, altered iron handling, impaired immune tolerance, and progressive loss of cells whose work is among the most ATP-intensive in the human body.

The standing rule (Compensatory-cascade) applies: when ATP load exceeds ATP-generating capacity, the system reverts to more primitive nests of energy production to defend persistence. Acute emergency-mode can be adaptive. Chronic lock-in is what we call disease. Barrier failure, metabolic endotoxemia, pathobiont bloom, parietal-cell attrition, and low ferritin that refuses to rise are readable as chronic-mode expressions on the GI dashboard — not freestanding villains inventing disease beside the engine.

Stay monist: Shore / Surf Judge language names orientation inside one field — not a second “mind stuff” beside mitochondria, and not a moral story in which “leaky gut” invents evil independent of cellular fuel handling (Dashboard-discipline: map ≠ terrain). The bioenergetics here follows Nick Lane’s work; cascade framing, Surfer/Energy Phase, and EN overlay are EnSurf’s own extensions, not Lane’s claims.

Metabolism is the higher-order regulator. Immunity, iron homeostasis, tissue architecture, and microbial ecology are effectors that respond to cellular energy production, redox balance, and substrate availability. When we treat only the effectors — suppress clones, replace missing iron and B12, monitor for neuroendocrine tumors, chase single probiotic strains — we are adjusting the dashboard while the engine continues to lose power.

2. Nested symbionts — mitochondria inside, gut biota outside

The eukaryotic cell itself arose through symbiosis. Current evidence points to an ancient merger in which an Asgard-archaea-lineage host formed a stable endosymbiotic relationship with an alphaproteobacterium that became the mitochondrion — supplying efficient oxidative phosphorylation while gaining a protected niche. That chimeric event endowed unprecedented energetic headroom. The mitochondrion’s bacterial ancestry explains its circular genome, independent division, and bacterial-like inner membrane.

The gut biota extends and externalizes this ancient pattern. While mitochondria reside inside our cells as permanent endosymbionts, the trillions of bacteria and archaea that colonize the gastrointestinal tract function as an ecological symbiont — an external metabolic organ whose collective genome and metabolism interface continuously with host physiology. Archaea such as Methanobrevibacter smithii consume hydrogen from bacterial fermentation, thermodynamically pulling carbohydrate breakdown forward. Humans encode roughly 20,000 protein-coding genes; the collective microbiome encodes an estimated 3 to 10 million. The hologenome expands metabolic and regulatory capacity the host genome alone cannot supply.

Essential microbial genetic contributions include: (1) carbohydrate-active enzymes (CAZymes) in polysaccharide utilization loci that unlock plant cell-wall polysaccharides and resistant starches the human genome barely touches, releasing substrates that become short-chain fatty acids (SCFAs); (2) vitamin biosynthesis pathways (several B vitamins and menaquinone / vitamin K2 in certain taxa) that become especially important during dietary insufficiency or malabsorption; (3) bile-acid transformation — deconjugation and 7α-dehydroxylation yielding secondary bile acids that signal through FXR and TGR5, regulating hepatic glucose/lipid metabolism, energy expenditure, and gut hormone release including GLP-1 as physiology, not as an invented drug protocol; (4) tryptophan and aromatic amino-acid metabolism into indoles and related AhR ligands that strengthen barrier function and modulate immune tone; (5) SCFA production — acetate, propionate, and especially butyrate — as fuel, GPCR ligands, and HDAC inhibitors that open chromatin at loci governing tight junctions, antimicrobial peptides, IL-10, and Foxp3+ regulatory T-cell differentiation.

Keystone mutualists such as Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, and Akkermansia muciniphila exert disproportionate influence. Pathobionts — certain adherent-invasive E. coli, sulfidogenic Bilophila wadsworthia, Proteobacteria blooms during antibiotic or inflammation-driven dysbiosis — are context-dependent: normally checked, pathogenic when ecological checks fail. Simplistic “good bug / bad bug” lists have limited clinical utility; restoration of diversity and keystone function often outperforms targeted elimination of any single organism.

Mitochondria and gut biota are two nested scales of bacterial symbiosis. The inner supplies ATP via OXPHOS; the outer supplies additional usable energy as SCFAs plus epigenetic and signaling molecules that allow the host genome to express its full metabolic and immune repertoire. When either partnership is compromised, energetic and regulatory coherence declines. Fuel Sage’s nested-symbiont hierarchy is the same geometry.

3. Colonocyte energetics and the barrier–inflammation axis

Nowhere is dependence on bacterial metabolism more direct than in the colonic epithelium. Colonocytes derive approximately 60–70% of their ATP from β-oxidation of butyrate and other SCFAs rather than from glucose or glutamine. Butyrate oxidation inside colonocyte mitochondria generates acetyl-CoA for the TCA cycle and OXPHOS — supporting ion transport, mucus secretion, and epithelial renewal every 3–5 days.

Butyrate’s role extends beyond fuel. It helps maintain crypt-base hypoxia favoring stem-cell quiescence and limiting facultative anaerobes and pathobionts; upregulates tight-junction proteins (ZO-1, occludin, claudins); stimulates goblet-cell differentiation and mucus; induces antimicrobial peptides; and promotes regulatory T-cell differentiation in the lamina propria — calibrating tolerance of commensals while preserving responsiveness to genuine threats.

High-quality fermented sources of microbiota-accessible carbohydrates — non-pasteurized organic sauerkraut, kimchi, real pickles, fermented onions and beets — deliver butyrate-pathway support with practical advantages named in the essay: lactic fermentation consumes simple sugars (lower glycemic/insulinemic impact than raw vegetables), reduces many plant anti-nutrients and toxins, and imposes less digestive burden, making these foods particularly compatible with ketogenic or low-carbohydrate metabolic states that support mitochondrial flexibility. Traditional ferments are a concentrated, low-drawback route to metabolites colonocytes and the broader holobiont require — hypothesis language, not a branded diet order.

When bacterial butyrate production falls — low MAC diversity, loss of butyrate-producing keystones, antibiotic disruption — colonocytes shift toward compensatory glycolysis (a Warburg-like pattern). ATP and epigenetic outputs fall; tight junctions loosen; mucus thins; barrier permeability to LPS, flagellin, and peptidoglycan rises. Metabolic endotoxemia activates TLR4 and related receptors, driving NF-κB, TNF-α, IL-6, IL-1β, and systemic low-grade inflammation. Inflammation further damages mitochondria; luminal oxygen, pH, and bile-acid shifts favor pathobionts; further loss of butyrate producers deepens the deficit. This feed-forward loop helps explain why IBD, metabolic syndrome, and aspects of depression and neurodegeneration often co-occur — and why restoring butyrate-producing capacity can produce multi-system benefits without promising cure on a schedule.

From a frugal-philosophy perspective, the colonocyte’s dependence on bacterial energy underscores a design principle: the eukaryotic gut was never engineered to run on host metabolism alone. Ultra-processed patterns low in accessible MACs and high in additives that erode mucus or select against butyrate producers are a mismatch at the level of epithelial energetics and barrier function.

4. Modern disruption — extinction, pathobionts, UPF, antibiotics

Contemporary Western lifestyles have precipitated measurable reduction in gut microbial diversity and depletion of keystone taxa once likely ubiquitous. Principal drivers: dietary collapse of complex-carbohydrate diversity and resistant-starch intake; pharmacological pulses (repeated or early-life antibiotics, acid-suppressing drugs, other ecology-altering agents); ecological loss of environmental microbial exposures (urbanization, cesarean delivery, formula feeding, diminished soil/animal/ferment contact). The result is a less functionally redundant ecosystem whose collective genetic output is diminished precisely where the host genome cannot compensate — complex carbohydrate degradation, butyrate synthesis, bile-acid transformation, tryptophan metabolism.

Loss of diversity is qualitative and self-reinforcing: an ecological ratchet. Missing functions are encoded in genomes of organisms that have been ecologically displaced, not merely numerically reduced — which is why probiotics alone often fail to reverse established dysbiosis. Ultra-processed foods compound the problem: emulsifiers that thin mucus and promote pathobiont adherence; non-nutritive sweeteners that alter composition and can impair glucose tolerance via microbiome-dependent pathways; hyper-rewarding sensory profiles that drive hedonic overconsumption while degrading the partnership that calibrates those same hormones (Hunger Code / defended-fat-mass adjacency — this page does not invent GLP-1 agonism protocols).

Antibiotics remain lifesaving in acute infection and also represent pulsed mass-extinction events. Recovery is often incomplete, especially after multiple courses or early-life exposure before ecological maturity. Associations with later obesity, asthma, IBD, and metabolic dysfunction are consistent with the hypothesis that primary-symbiont integrity during critical windows sets long-term metabolic and immune trajectories. Functional output — butyrate production, BSH activity, competitive exclusion — matters more than any single species count. Restoration should prioritize functional redundancy through high-quality fermented MAC sources that feed multiple butyrate-producing pathways over species richness theater alone.

The net result is a hologenome with a reduced metabolic and regulatory toolkit: partial metabolic and epigenetic insufficiency even when dietary macronutrients are abundant — the cluster of “diseases of civilization” whose rising prevalence tracks ultra-processed diets and antibiotic use.

5. Autoimmune gastritis — parietal energetics, ferritin sentinel, immune crosstalk

On Sage — Autoimmune Gastritis.

6. Diet context — raw-plant limits vs fermented MAC partnership

A diet built predominantly on raw or minimally processed vegetables is frequently advanced as anti-inflammatory. In AIG and the broader holobiont framework it carries important limitations named in the essay.

Bioavailability. Heme iron, preformed B12, and amino-acid profiles critical for mitochondrial biogenesis and membrane repair are absent or poorly absorbed from plant sources. In achlorhydria and intrinsic-factor deficiency, reliance on non-heme iron and plant precursors becomes even less tenable. Isolated supplements can paper over some gaps; they do not restore the evolutionary package of animal-sourced nutrients parietal cells and immune cells evolved to expect.

The raw state. Many plant secondary compounds (oxalates, lectins, phytates, goitrogens) are reduced by cooking or fermentation. In a gut already compromised by low acid and altered microbiota, high intakes of unprocessed plant material can increase antigenic load and further disrupt symbiotic dialogue. Fermented MACs deliver fiber substrate plus live or residual microbial metabolites that support butyrate production and immune education. Raw volume without fermentation does not reliably achieve the same end.

Energetic and membrane requirements. Mitochondrial and plasma membranes of highly active cells require specific fatty-acid compositions and cholesterol. Strict exclusion of animal fats removes a ready source of these lipids and accompanying fat-soluble vitamins. Evolution selected a partnership between eukaryotic host metabolism (supported by animal and fermented foods) and a diverse microbial consortium fed by complex plant polysaccharides rendered more bioavailable by traditional preparation — not a pure plant ideology.

None of this argues for the absence of plants. It argues against elevating a raw or exclusively plant-based pattern as universally optimal when the clinical picture already includes malabsorption and mitochondrial strain. Context, absorption capacity, and the full nutrient matrix matter more than dietary purity.

7. Reframing disease — siloed pathologies as holobiont expressions

If primary symbiosis is the upstream determinant of metabolic coherence, many named chronic diseases can be reconceived as downstream expressions of its compromise. Atherosclerosis is not merely lipid storage; it is inflammatory response to endothelial injury in which metabolic endotoxemia, oxidized lipoproteins, and mitochondrial dysfunction interact — endotoxemia frequently tracing to barrier failure from inadequate butyrate and keystone loss (Cardiac Sage adjacency). Neurodegenerative conditions acquire a gut-origin dimension via reduced neuroprotective microbial metabolites (IPA, certain secondary bile acids, butyrate), systemic inflammation compromising the blood–brain barrier, and altered vagal/enteroendocrine signaling (Brain Sage). Autoimmune and allergic diseases reflect failed immune education when SCFA/indole/polysaccharide-A ligands for regulatory pathways are impoverished. Obesity, type 2 diabetes, and NAFLD show clearer etiology when microbial set-points for insulin sensitivity and satiety signaling sit at the center — physiology of enteroendocrine signaling is not a retail prescription.

This reframing does not deny organ-specific or symptom-directed interventions when acute suffering or organ failure demands them. It suggests the long-term strategy for the chronic-disease epidemic must address integrity of the primary symbiosis rather than endlessly subdividing downstream manifestations. The eye — mitochondria-rich, high-energy tissue — frequently registers upstream shifts earlier than other organs; subclinical retinal and choroidal changes in metabolic syndrome are consistent with ocular tissues as sentinels of holobiont energetic coherence (Eye Sage as canary, not a claim this page invents new ocular protocols).

8. Why the conventional paradigm is structurally limited / Surf Judge

Precision immune interventions that temper specific autoreactive clones can limit ongoing tissue destruction and create space for recovery. They are not inherently “chasing downstream” if clonal expansion actively drives the inflammatory loop. Yet if the higher-order metabolic state continues to favor effector over regulatory phenotypes and to generate mitochondrial damage signals, the same clones or new ones are likely to re-emerge. Iron and B12 must still be replaced — often parenterally at first in essay language — because absorption machinery is damaged. Full iron panels, inflammatory markers, and redox indicators guide better than ferritin alone. The goal is not merely to normalize numbers but to restore conditions under which those numbers remain normal without perpetual supplementation.

  • Suppressing acid without asking why parietal energetics failed trades one dashboard for another.
  • Oral iron theater against achlorhydria and inflammatory sequestration often fails while the engine stays under power.
  • Probiotic strain shopping without fermented MAC diversity and host mitochondrial support rarely restores displaced keystone genomes.
  • Ideological raw-plant maximalism in malabsorbing AIG can worsen antigenic load and cofactor gaps.
  • Institutional incentives favor identifiable lifelong replacements and symptom suppression over root-cause restoration that may reduce long-term pharmacotherapy.

Map ≠ terrain: gastrin, pepsinogen, intrinsic factor antibodies, ferritin, B12, fecal calprotectin, microbiome diversity scores, and endoscopy are indispensable dashboards. They are not the organism’s Level 0–1 field. Treating the dashboard as the disease while mismatch continues is the Good Doctor’s named error mode. Treating the constraint — restore oxidative capacity, holobiont coherence, fermented MAC partnership, circadian order, absorptive conditions — is complementarity, not ideology against gastroenterology.

9. Frugal restoration of the partnership (hypothesis logic, not orders)

The hypothesis predicts that interventions shown to improve mitochondrial function and gut-symbiont coherence should, over time, slow or partially reverse progressive parietal-cell loss and improve iron dynamics beyond replacement alone — and produce coordinated improvements across seemingly disparate conditions when butyrate-producing capacity and barrier integrity recover. the bullets below are hypothesis language, not a home protocol, not clinical dosing schedules, and not peptide/HRT/GLP-1 invention. Longitudinal pre-diagnostic mitochondrial and microbiome metrics are still lacking; relative genetic, infectious, and metabolic weighting varies among individuals.

  • Fuel / fermented MACs: Regular inclusion of diverse traditionally fermented vegetables and other high-quality fermented MAC sources; adequate high-quality animal protein and fat supporting host mitochondrial function (ketones, creatine, carnitine adjacency named in the essay); prudent avoidance of ultra-processed items and emulsifiers that erode mucus. Prefer fermented over raw volume when acid and microbiota are already compromised. Hypothesis, not a branded diet order.
  • Circadian: Light exposure, feeding windows, sleep timing that support mitochondrial and barrier resilience; time-restricted eating or intermittent fasting windows may periodically reduce substrate load and inflammatory pressure where medically appropriate — not a Surfer challenge, and not for every candidate.
  • Strength: Progressive resistance and movement patterns that enhance insulin sensitivity and inflammatory resolution — conditions under which a diverse microbiome can re-establish itself.
  • Antibiotic and acid-drug stewardship: Use when clinically required; when used, prompt reintroduction of high-quality ferments deserves systematic study as restoration strategy — not DIY antibiotic avoidance of indicated infection care.
  • Early-life seeding (population leverage): Vaginal delivery when safe, skin-to-skin, breastfeeding set trajectories difficult to fully reverse later — public-health investment language, not a rebuke of necessary obstetric care.
  • Replacement where machinery is damaged: Iron and B12 replacement remain necessary when absorption is broken — often parenteral first — guided by fuller panels than ferritin alone. Ask why absorption failed before lifelong oral megadose theater.
  • Targeted immune control when clones drive the loop: Pair effector tempering with aggressive restoration of the metabolic orchestrator — mitochondrial biogenesis and quality control, redox balance, substrate matched to absorptive capacity, circadian alignment, metabolically competent biota.
  • Adjuncts stay adjuncts: Expensive exotic probiotics, continuous monitors, and specialty stacks are not first-line frugal measures once foundations are named; targeted adjuncts may become rational after core dietary and lifestyle foundations and individual response tracking — still not dosing invention on this page. Methylene Blue and other bioenergetic supports have their own pages.

Testable predictions from the expanded hypothesis: populations increasing high-quality fermented MAC intake while reducing UPF and unnecessary antibiotic exposure should show rises in fecal butyrate, improvements in barrier/endotoxemia markers, better insulin sensitivity and hunger regulation, and lower incidence or severity of the cluster currently labeled as separate diseases. Functional-metagenomic metrics should correlate more tightly with multi-system trajectories than many single-analyte biomarkers. These predictions are falsifiable.

10. Continuity with the metabolic philosophy series

This GI hub is continuous with earlier essays. Fuel positions nested symbionts and fermented MACs as board architecture. Immune and Inflammation locate effector attacks downstream of metabolic orchestrator failure. Thyroid names holobiont compromise as cofactor and endotoxemia terrain for the HPT dashboard. Obesity and Diabetes sit on microbial modulation of satiety and insulin set-points without authorizing GLP-1 protocol invention. Cardiac reads endotoxemia into vascular inflammation. Brain extends gut-origin metabolites into CNS proteostasis. Eye remains a high-watt sentinel. Philosophy of Medicine names chronic disease as compensatory-mode lock-in. The same upstream logic — bioenergetic insufficiency, holobiont fraying, membrane and redox injury — unifies these domains. Durable improvement requires restoration of conditions under which metabolic persistence and primary symbiosis can be fully expressed, not merely pharmacological suppression of downstream readouts.

  • Cancer — CRC: adenoma as dashboard of colonocyte—mito—microbiome field defect; same holobiont partnership, oncology reading.
  • Fuel — nested symbionts; animal fats/proteins; fermented MACs; seed-oil membrane injury; timing.
  • Immune — orchestrator vs effector; immunometabolism; tolerance education by microbial ligands.
  • Thyroid — holobiont interface for selenium/zinc economy and endotoxemia that shifts the HPT dashboard.
  • Obesity · Diabetes — defended fat mass, insulin sensitivity, satiety signaling modulated by microbial metabolites.
  • Cardiac — metabolic endotoxemia and vascular inflammatory phenotype.
  • Brain — gut–brain axis metabolites, barrier, neuroinflammation adjacency.
  • Eye — canary / sentinel of holobiont energetic coherence.
  • Signals — enteroendocrine and bile-acid signaling as higher coordination (peptide/HRT/GLP-1 protocols).
  • Dental — oral–gut ecological continuity named in the essay’s Related list.
  • Reproductive / Infertility — systemic inflammation and absorption terrain feeding gamete energetics adjacency.
  • Philosophy of Medicine — disease as chronic compensatory mode; Good Doctor ethos; map ≠ terrain.

12. Limits of the claim

  • Working hypothesis. Not a randomized-trial verdict that fermented-MAC / mitochondrial-first strategies outperform guideline gastroenterology, iron/B12 replacement, H. pylori care, or IBD specialty protocols as monotherapy.
  • Does not deny true autoimmune destruction, H. pylori disease, celiac clocks, IBD as entities, gastric malignancy surveillance, or the clinical utility of acid suppression and parenteral replacement when indicated.
  • GI bleeding, perforation, obstruction, acute abdomen, alarm-feature weight loss, and neuroendocrine tumor clocks remain high-stakes; specialty care owns those clocks.
  • no peptide/HRT/GLP-1 protocols; no clinical dosing invention beyond hypothesis language.

13. Conclusion — steward the primary partnership

The gut biota is not an accessory or recent afterthought. It is the living continuation of the Archaea–Bacteria symbioses that first made eukaryotic complexity — and therefore human biology — possible. Mitochondria represent the permanent intracellular endosymbiont; the gut community represents its ecological counterpart. When this primary symbiosis is intact and diverse, the organism exhibits metabolic flexibility, appropriate inflammatory tone, stable defended body composition, and coherent gene expression across scales. When it is disrupted, the system shifts into compensatory rigidity whose varied clinical expressions we label as separate diseases — including autoimmune gastritis with its ferritin sentinel and parietal energetic failure.

Modern environments have imposed unprecedented stressors: collapse of dietary complex-carbohydrate diversity, chemical and pharmaceutical disruption, reduced environmental microbial exchange. Treating an obligate symbiont as optional predicts the diseases of civilization. A metabolic hypothesis of eukaryote–gut biota symbiosis — and of autoimmune gastritis as one coherent downstream expression — calls for reorientation: honor both the mitochondrial endosymbiont and the bacterial–archaeal community, favor fermented MAC sources that deliver what the microbiome needs with fewest drawbacks to host mitochondrial priorities, replace what broken absorption cannot take up, and temper effectors when clones drive destruction — without mistaking dashboard management for engine restoration.

This is not a rejection of acute or organ-specific medicine when suffering demands it. It is an insistence that the long-term solution lies in restoring the terms of an ancient symbiosis rather than endlessly managing its fragmented failures. Feedback and collaborative refinement are welcomed. The goal remains understanding and restoring the engine. Offered as a working hypothesis, not clinical advice.

Topics in this chapter

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

See the notice at the top of this page. Working hypothesis, not medical advice.